Metoject (Methotrexate)

Methotrexate blocks dihydrofolate reductase, an enzyme needed to produce tetrahydrofolate, a co‑factor for DNA synthesis. By limiting nucleotide formation, it hampers the replication of rapidly dividing cells such as immune‑system lymphocytes and malignant cancer cells, producing immunosuppressive and antineoplastic effects.

The specific dose of Metoject is individualized by the prescribing clinician based on the patient’s diagnosis, disease severity, renal and hepatic function, and response to therapy. Dosing regimens may vary widely, so the prescriber determines the appropriate amount and schedule.

Methotrexate is known to be teratogenic and can cause fetal malformations. It is contraindicated in pregnancy and women of child‑bearing potential are advised to use effective contraception. Limited data exist for breastfeeding, and the drug is generally avoided because it can be excreted in milk.

To request Metoject, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Compared with biologic agents, methotrexate is a small‑molecule antimetabolite that is less expensive and can be administered via injection. It is often used as first‑line therapy for rheumatoid arthritis and psoriasis, while biologics may be added for patients who do not achieve adequate control. In oncology, methotrexate is a cornerstone chemotherapeutic, whereas newer targeted agents may be used in combination.

Metoject should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If a short period at room temperature is unavoidable, limit exposure to no more than a few hours before use.

Metoject is supplied as a sterile injectable solution and can be given intramuscularly, intravenously, or subcutaneously, depending on the clinical indication and prescriber preference. Administration is performed by a qualified healthcare professional using aseptic technique, and the injection site is selected according to standard practice.

The most serious adverse events include severe liver toxicity, pulmonary fibrosis or interstitial pneumonitis, bone‑marrow suppression leading to life‑threatening cytopenias, and renal failure. Additionally, methotrexate is highly teratogenic, and patients must avoid pregnancy during treatment and for a defined period after discontinuation.

Metoject is contraindicated in patients with known hypersensitivity to methotrexate, severe renal or hepatic impairment, active uncontrolled infections, and in pregnant or breastfeeding women. Caution is also advised for individuals with pre‑existing blood dyscrasias or pulmonary disease.